Table 1. Baseline characteristics of participants. Values are numbers (percentages) unless stated otherwise

Characteristic Placebo (n=215) Galantamine 24 mg (n=220) Galantamine 32 mg (n=218)

Demography

  Men/women 83/132 81/139 80/138

Mean (SD) age (years) 72.7 (7.6) 71.9 (8.3) 72.1 (8.6)

Clinical

  Mean (SD) weight (kg) 67.2 (12.1) 66.7 (12.8) 66.2 (13.4)

No (%) of smokers 193 (90) 200 (91) 199 (91)

Other active medical conditions 154 (72) 159 (72) 168 (77)

No (%) with apolipoprotein E4 allele^*

  Homozygous 34 (18) 32 (17) 27 (15)

  Heterozygous 83 (45) 97 (53) 95 (53)

Mean (SD) mini-mental state examination score 19.3 (3.5) 19.5 (3.4) 19.0 (3.8)

Mean (SD) Alzheimer's disease assessment scale score 24.7 (9.3) 25.4 (9.4) 26.2 (10.4)

Mean (SD) disability assessment in dementia score 66.6 (22.5) 69.9 (21.4) 69.6 (20.6)

Mean (SD) time since cognitive problem diagnosed (years) 3.5 (2.3) 3.6 (2.7) 3.7 (2.2)

Mean (SD) time since probable Alzheimer's disease diagnosed (years) 0.8 (1.0) 0.9 (1.2) 0.8 (1.0)

Brain imaging findings

  Territorial infarctions 1 (0.5) 7 (3) 2 (1)

Lacunar infarctions 17 (8) 10 (5) 16 (7)

White matter lesions 0 0 2 (1)

Tumour 0 1 (0.5) 1 (0.5)

^* n=185 for placebo, n=184 for galantamine 24 mg, and n=179 for galantamine 32 mg.

11 item cognitive subscale.

Computed tomography or magnetic resonance imaging findings in past 12 months.